title: Adjuvant properties of Propionibacterium avidum KP-40 in vaccination against endemic viral and bacterial infections. II. Swine immunized with inactivated Haemophilus pleuropneumoniae vaccine and experimentally infected with different virulent serotypes of H. pleuropneumoniae.
abstract: Forty 3-month old swine were treated with immunomodulating Propionibacterium avidum KP-40 (PA) and/or vaccinated with a formalin-inactivated mixture of serotypes 1, 3, 5 and 9 of Haemophilus pleuropneumoniae (Pleurovac). Three weeks after revaccination all animals were inoculated with viable single serotypes of Haemophilus pleuropneumoniae. The IgG antibodies induced by vaccination agglutinated all serotypes of Haemophilus pleuropneumoniae, except for serotype 5. Antibody titers were not influenced by the application of PA together with the vaccine. Infection of vaccinated piglets resulted in the development of pleuropneumonia in 8 out of 10 animals, while vaccination together with application of PA lowered the morbidity rate to 1 out of 10 (p < 0.05). The usefulness of a PA prophylaxis was also demonstrated in non-vaccinated piglets infected with Haemophilus pleuropneumoniae. Because of the considerable variability of strains and serotypes of Haemophilus pleuropneumoniae and the generally low prophylactic potency of pleuropneumonia vaccines it is concluded that long-lasting enhancement of non-specific antiinfective resistance caused by PA may lower the risk of endemic infections in vaccinated piglets.
authors.affiliation: Department of Swine Diseases, National Institute of Veterinary Research, Pulawy, Poland.
authors.forename: I
authors.initials: I
authors.lastname: Markowska-Daniel
authors.forename: Z
authors.initials: Z
authors.lastname: Pejsak
authors.forename: S
authors.initials: S
authors.lastname: Szmigielski
authors.forename: G
authors.initials: G
authors.lastname: Sokolska
authors.forename: J
authors.initials: J
authors.lastname: Jeljaszewicz
authors.forename: G
authors.initials: G
authors.lastname: Pulverer
mesh_terms: D000189:Actinobacillus Infections / Q000517:prevention & control / Q000662:veterinary; D016977:Actinobacillus pleuropneumoniae / Q000145:classification / Q000276:immunology* / Q000472:pathogenicity; D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D001428:Bacterial Vaccines / Q000008:administration & dosage*; D005069:Evaluation Studies as Topic; D007074:Immunoglobulin G / Q000096:biosynthesis; D011424:Propionibacterium / Q000276:immunology*; D012703:Serotyping; D013552:Swine; D013553:Swine Diseases / Q000517:prevention & control; D015164:Vaccines, Inactivated / Q000008:administration & dosage; D014774:Virulence
chemical_list: D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D007074:Immunoglobulin G; D015164:Vaccines, Inactivated